Social Responsibility

Novartis Australia responds to funding challenges faced by patient organisations during COVID-19

Health Industry Hub | May 29, 2020 |
[Total: 1    Average: 5/5]

Novartis is responding to the challenges faced by patient organisations with the announcement of three key initiatives to help them continue their critical work throughout the COVID-19 crisis.

The initiatives provide funding and support at a time when resources are being diverted to help manage the critical and ongoing patient and caregiver need for COVID-19 related information, education, psychological support and health system navigation.

Novartis ANZ Country President, Richard Tew said, “Novartis regularly engages with and listens to the patient community, and we have heard that this is a worrying time for people with health conditions and their carers. Now, more than ever, patient organisations are needed to provide information, advocacy and essential services to those who need it most throughout the pandemic.

Register & join 22,000+ industry professionals in reading the latest industry news & engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.

“To show our ongoing commitment to our partners, Novartis is proud to offer funding for COVID-19 related initiatives or COVID-19 impacted programs to our existing patient organisation partners. We are prioritising and expediting funding requests that address the immediate needs of those patients impacted by the pandemic, to ensure patient organisations can continue to provide much needed education and support for patients and their families during this time”, continued Richard.

“Furthermore Novartis acknowledges the additional workload and strain on employees of those organisations. Anecdotal feedback from patient organisations suggests that the crisis may be having an indirect impact on the mental health and wellbeing of staff, and we are pleased to offer employees of our partner patient organisations access to our local employee assistance program (EAP).”

In alignment with the Government’s mental health initiative the #SelfcareInHealthcare campaign has been launched to support Pharma, Biotech and MedTech industry professionals. The initiative is supported by Medicines Australia, AusBiotech, MTAA and ARCS Australia. Learn more.

Employees of partner patient organisations will have access to Novartis’ EAP for a six-month period, commencing from the start of May until the end of November 2020. The service mirrors the service already provided for local Novartis employees. The EAP connects employees to immediate and confidential counselling support services, as well as specialised support for leaders and managers within their organisations.

One organisation to benefit from the COVID-19 funding is MS Research Australia for the Australian Multiple Sclerosis Longitudinal Study (AMSLS), Australia’s longest running and largest study of people with MS.

Dr Julia Morahan, Head of Research from MS Research Australia said, “The not for profit sector has been impacted significantly by the pandemic and it is disrupting funding sources for vital research. Support such as the COVID-19 funding from Novartis is important because it enables us to maintain our focus on research and programs so we can kiss goodbye to MS forever.”

“We are delighted that Novartis has also supported MS Research Australia by creating a team of associates who are personally walking, running and fundraising throughout the month of May for the May 50k (may50k.org).”

Further external training and support resources are being offered to local partner patient organisations by the global Novartis organisation. These resources includes topics relating to dealing with complexity, remote working, parenting, mindfulness and managing stress.

Additionally, Novartis has increased internal and external promotion of patient organisation campaigns to ensure greater visibility of key activities and events.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - Private health insurer looking to invest in Australian private hospitals

Private health insurer looking to invest in Australian private hospitals

Health Industry Hub | July 15, 2020 |

MedTech News: In a recent opinion piece Dr Bill Coote, former AMA Secretary General and former Director of the Medicare […]

More


News & Trends - Pharmaceuticals

Pharma News - Merck Australia supports the first Australian-developed COVID-19 vaccine - Sypharma and Vaxine

Merck Australia supports the first Australian-developed COVID-19 vaccine

Health Industry Hub | July 15, 2020 |

Pharma News: Sypharma, an Australian biopharmaceutical formulation company, announced manufacturing of COVAX-19 and Advax adjuvant for Covid-19 in partnership with […]

More


News & Trends - Pharmaceuticals

Pharma News - Precision prescribing to combat Australia’s expected surge in mental illness

Precision prescribing to combat Australia’s expected surge in mental illness

Health Industry Hub | July 15, 2020 |

Pharma News: COVID-19 social isolation, familial and community disconnection, shock, job loss and health fears create the perfect storm for […]

More


Medical

Medical Pharma Biotech MedTech - $47M accelerator program for MedTech, Biotech and Pharma sectors in diabetes and cardiovascular disease

$47M accelerator program for MedTech, Biotech and Pharma sectors in diabetes and cardiovascular disease

Health Industry Hub | July 15, 2020 |

Medical News: The operation of the Australian Government’s $47 million Targeted Translation Research Accelerator (TTRA) initiative for diabetes and cardiovascular […]

More